Towards a new therapy
for the treatment of
Malignant Mesothelioma
A Novel BERberine derivative for Malignant MESothelioma
Asbestos exposure is the main risk factor for malignant mesothelioma. This rare and lethal cancer affects the mesothelium: the protective thin layer of tissue that covers many of the internal organs of the body. The tumour has a long latency period taking 20 to 50 years to appear. Because of its aggressiveness and highly resilience, researchers are on the hunt for newer and better treatment strategies. This is indeed the main goal of BERMES: developing a novel molecule with a disruptive mechanism of action that has shown activity in this hard-to-treat tumour.
WATCH VIDEO ►
Follow the most recent news of the project in Twitter @BermesProject
Malignant mesothelioma is a rare, aggressive and highly resilient malignancy that affects the arising in the thin layer of tissue known as mesothelium, which covers many of the important internal organs like the lungs, the peritoneal cavity, the heart and the testis.
NAX035 is a novel and selective anticancer agent with a superior profile for oncology conditions. It is a derivative of natural alkaloid Berberine which shows superior activity and pharmacology and safety profile. It shows robust preclinical proof of concept in several in vitro and animal models.
Aromics, and its CEO Dr. Plasencia have been part of the delegation of Catalan...
Aromics and Bermes project will be present in next BIOJAPAN 2024, celebrated...
